SURENDRA K AJJARAPU
CIK 1368298 · Chairman and CEO · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$28.49M
Companies
5
Total Filings
21
Lifetime Open-Market Net
$130.01M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGRX | Director | 7,971,511 | $3.52 | $28.06M | $0 | 4 | 2026-06-25 |
| MEDS | Chairman and CEO | 120,844 | $3.55 | $429.0K | $130.01M | 7 | 2024-05-28 |
| Tevogen Bio Holdings Inc. (LGSTW) Delisted | CEO and Chairman | 8,988,889 | $0.06 | $540.2K | $0 | 2 | 2023-06-21 |
| Ocean Biomedical, Inc. (OCEAW) Delisted | Director | 258,200 | $0.03 | $7.7K | $0 | 2 | 2023-03-24 |
| Ocean Biomedical, Inc. (AEHAW) Delisted | Chief Executive Officer | — | $0.16 | — | $0 | 1 | 2021-12-16 |
Recent Filings · Page 2 of 3
21 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-09-16 | MEDS | Grant (A) | +51,724 | $0 | EDGAR |
| 2022-05-23 | MEDS | Buy (P) | +10,000 | $130.00M | EDGAR |
| 2022-05-23 | MEDS | Buy (P) | +10,000 | $13.0K | EDGAR |
| 2021-12-16 | Ocean Biomedical, Inc. (AEHAW) Delisted | Other (J) | — | $0 | EDGAR |
| 2020-06-16 | MEDS | Other (J) | −201,613 | $0 | EDGAR |
| 2020-04-15 | MEDS | Grant (A) | +123,504 | $755.8K | EDGAR |
| 2019-05-14 | — | Grant (A) | — | $0 | |
| 2018-02-12 | — | Sell (S) | −250,000 | -$28.12B | |
| 2017-04-24 | — | Gift (G) | −156,250 | -$15.87B | |
| 2008-06-23 | — | Grant (A) | — | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.